Search Results - "Spurgeon, S. E."

Survival trends in T cell prolymphocytic leukemia: A SEER database analysis by Chandran, Rekha, Gardiner, S. K., Fenske, T. S., Spurgeon, E. S.

Get full text

CX-4945, a selective inhibitor of casein kinase-2 (CK2), exhibits anti-tumor activity in hematologic malignancies including enhanced activity in chronic lymphocytic leukemia when combined with fludarabine and inhibitors of the B-cell receptor pathway by Prins, R C, Burke, R T, Tyner, J W, Druker, B J, Loriaux, M M, Spurgeon, S E

Get full text

Zilovertamab vedotin (MK‐2140) in relapsed or refractory (R/R) non‐Hodgkin lymphoma (NHL): 14‐month follow‐up of the phase 1 waveLINE‐001 study by Wang, M. L., Mei, M., Barr, P. M., Barrientos, J. C., Vos, S., Furman, R. R., Patel, K., Wierda, W. G., Choi, M. Y., Kallam, A., Wang, S., Ogbu, U. C., Marinello, P., Spurgeon, S. E.

Get full text

P1231: ZILOVERTAMAB VEDOTIN (MK‐2140) FOR THE TREATMENT OF NON‐HODGKIN LYMPHOMA: THE PHASE 1 DOSE ESCALATION AND COHORT EXPANSION WAVELINE‐001 STUDY OF AN ANTI‐ROR1 ANTIBODY‐DRUG CONJUGATE by Wang, M., Mei, M., Barr, P. M., Barrientos, J., Vos, S., Furman, R., Patel, K., Thompson, P. A., Choi, M., Kallam, A., Zhu, Y., Chakraborty, S., Marinello, P., Spurgeon, S. E.

Get full text

S209: PRIMARY RESULTS FROM THE PHASE 3 SHINE STUDY OF IBRUTINIB IN COMBINATION WITH BENDAMUSTINE‐RITUXIMAB (BR) AND R MAINTENANCE AS A FIRST‐LINE TREATMENT FOR OLDER PATIENTS WITH MANTLE‐CELL LYMPHOMA by Wang, M. L., Jurczak, W., Jerkeman, M., Trotman, J., Zinani, P. L., Belada, D., Boccomini, C., Flinn, I. W., Giri, P., Goy, A., Hamlin, P. A., Hermine, O., Hernández‐Rivas, J.‐Á., Hong, X., Kim, S. J., Lewis, D., Mishima, Y., Özcan, M., Perini, G. F., Pocock, C., Song, Y., Spurgeon, S. E., Storring, J. M., Walewski, J., Zhu, J., Qin, R., Henninger, T., Deshpande, S., Howes, A., Le Gouill, S., Dreyling, M.

Get full text

Classification and regression tree analysis for the prediction of aggressive prostate cancer on biopsy by Spurgeon, Stephen E F, Hsieh, Yi-Ching, Rivadinera, Adrianna, Beer, Tomasz M, Mori, Motomi, Garzotto, Mark

“…Prostate cancer screening allows early cancer detection but not all patients benefit from subsequent therapy. Thus, identifying patients who are likely to…”
Get more information

Cladribine plus rituximab for the initial treatment of mantle cell lymphoma by Pindyck, T., Spurgeon, S. E., Okada, C. Y., Epner, E. E.

“…Abstract only…”
Get full text

Targeting the epigenome: A phase I/II study of vorinostat (SAHA), cladribine (2-CdA), and rituximab in relapsed B-cell malignancies by Spurgeon, S. E., Okada, C. Y., Huang, J., Phillips, J., Epner, E. E.

“…Abstract only…”
Get full text

Activity of vorinostat (SAHA), cladribine (2-CdA), and rituximab in previously untreated mantle cell lymphoma: A phase I/II study by Spurgeon, S. E. F., Chen, A. I., Ratterree, B., Okada, C., Palmbach, G., Diaz, K., Subbiah, N., Capper, C., Epner, E. E.

“…Abstract only…”
Get full text

Phase I study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3‐kinase P110d, in patients with previously treated chronic lymphocytic leukemia by Coutre, S. E., Byrd, J. C., Furman, R. R., Brown, J. R., Benson, D. M., Wagner-Johnston, N. D., Flinn, I. W., Kahl, B. S., Spurgeon, S. E. F., Lannutti, B. J., Hsu, H. K. W., Ulrich, R., Peterman, S., Holes, L., Miller, L. L., Yu, A. S.

“…Abstract only…”
Get full text